Eveliqure's effort to develop a Shigella-ETEC combination vaccine is supported by the Wellcome Trust
- EVI
- Nov 5, 2019
- 1 min read
Updated: Dec 20, 2019
Eveliqure's effort to develop a Shigella-ETEC combination vaccine for travellers and children in resource poor countries is supported by the Wellcome Trust.
Eveliqure Biotechnologies announces today the grant of a Wellcome Trust Innovator Award that supports the early clinical development of its Shigella-ETEC combination vaccine with ~£500K and complements the previously secured ~€11 million funding from public sources for the vaccine’s development (Horizon2020, Austrian Wirtschaftsservice (AWS) and Austrian Research Promotion Agency, FFG).
To read the full news release, please click this link:
Comments